151 related articles for article (PubMed ID: 10830781)
21. Genomic aberrations are rare in urothelial neoplasms of patients 19 years or younger.
Wild PJ; Giedl J; Stoehr R; Junker K; Boehm S; van Oers JM; Zwarthoff EC; Blaszyk H; Fine SW; Humphrey PA; Dehner LP; Amin MB; Epstein JI; Hartmann A
J Pathol; 2007 Jan; 211(1):18-25. PubMed ID: 17072825
[TBL] [Abstract][Full Text] [Related]
22. Role of loss of heterozygosity on chromosomes 8 and 9 in the development and progression of cancer bladder.
Abdel Wahab AH; Abo-Zeid HI; El-Husseini MI; Ismail M; El-Khor AM
J Egypt Natl Canc Inst; 2005 Dec; 17(4):260-9. PubMed ID: 17102820
[TBL] [Abstract][Full Text] [Related]
23. P53 mutation and LOH at chromosome 9 in urothelial carcinoma.
Beothe T; Nagy A; Farkas L; Kovacs G
Anticancer Res; 2012 Feb; 32(2):523-7. PubMed ID: 22287741
[TBL] [Abstract][Full Text] [Related]
24. Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer.
Chow NH; Cairns P; Eisenberger CF; Schoenberg MP; Taylor DC; Epstein JI; Sidransky D
Int J Cancer; 2000 Nov; 89(6):514-8. PubMed ID: 11102896
[TBL] [Abstract][Full Text] [Related]
25. Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma.
Cheng L; Jones TD; McCarthy RP; Eble JN; Wang M; MacLennan GT; Lopez-Beltran A; Yang XJ; Koch MO; Zhang S; Pan CX; Baldridge LA
Am J Pathol; 2005 May; 166(5):1533-9. PubMed ID: 15855652
[TBL] [Abstract][Full Text] [Related]
26. Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer.
Stoehr R; Wissmann C; Suzuki H; Knuechel R; Krieg RC; Klopocki E; Dahl E; Wild P; Blaszyk H; Sauter G; Simon R; Schmitt R; Zaak D; Hofstaedter F; Rosenthal A; Baylin SB; Pilarsky C; Hartmann A
Lab Invest; 2004 Apr; 84(4):465-78. PubMed ID: 14968126
[TBL] [Abstract][Full Text] [Related]
27. Identification of chromosome 9 alterations and p53 accumulation in isolated carcinoma in situ of the urinary bladder versus carcinoma in situ associated with carcinoma.
Hopman AH; Kamps MA; Speel EJ; Schapers RF; Sauter G; Ramaekers FC
Am J Pathol; 2002 Oct; 161(4):1119-25. PubMed ID: 12368185
[TBL] [Abstract][Full Text] [Related]
28. Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer.
Bartoletti R; Cai T; Nesi G; Roberta Girardi L; Baroni G; Dal Canto M
J Surg Res; 2007 Dec; 143(2):422-7. PubMed ID: 17612565
[TBL] [Abstract][Full Text] [Related]
29. Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors.
Orlow I; Lianes P; Lacombe L; Dalbagni G; Reuter VE; Cordon-Cardo C
Cancer Res; 1994 Jun; 54(11):2848-51. PubMed ID: 8187066
[TBL] [Abstract][Full Text] [Related]
30. Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder.
Keen AJ; Knowles MA
Oncogene; 1994 Jul; 9(7):2083-8. PubMed ID: 8208555
[TBL] [Abstract][Full Text] [Related]
31. Oligoclonality of early lesions of the urothelium as determined by microdissection-supported genetic analysis.
Stoehr R; Hartmann A; Hiendlmeyer E; Mürle K; Wieland W; Knuechel R
Pathobiology; 2000; 68(4-5):165-72. PubMed ID: 11279342
[TBL] [Abstract][Full Text] [Related]
32. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer.
Czerniak B; Chaturvedi V; Li L; Hodges S; Johnston D; Roy JY; Luthra R; Logothetis C; Von Eschenbach AC; Grossman HB; Benedict WF; Batsakis JG
Oncogene; 1999 Feb; 18(5):1185-96. PubMed ID: 10022124
[TBL] [Abstract][Full Text] [Related]
33. The random development of LOH on chromosome 9q in superficial bladder cancers.
van Tilborg AA; de Vries A; de Bont M; Groenfeld LE; Zwarthoff EC
J Pathol; 2002 Nov; 198(3):352-8. PubMed ID: 12375268
[TBL] [Abstract][Full Text] [Related]
34. Tumour suppressor gene (CDKNA2) status on chromosome 9p in resected renal tissue improves prognosis of localised kidney cancer.
El-Mokadem I; Kidd T; Pratt N; Fleming S; Nabi G
Oncotarget; 2016 Nov; 7(45):73045-73054. PubMed ID: 27682877
[TBL] [Abstract][Full Text] [Related]
35. Chromosomal imbalances in successive moments of human bladder urothelial carcinoma.
Nascimento e Pontes MG; da Silveira SM; Trindade Filho JC; Rogatto SR; Viana de Camargo JL
Urol Oncol; 2013 Aug; 31(6):827-35. PubMed ID: 21763161
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of allelotype profiling for urothelial carcinoma.
Tzai TS; Chen HH; Chan SH; Ho CL; Tsai YS; Cheng HL; Dai YC; Lin JS; Yang WH; Chow NH
Urology; 2003 Aug; 62(2):378-84. PubMed ID: 12893368
[TBL] [Abstract][Full Text] [Related]
37. Loss of heterozygosity at 1p, 8p, 10p, 13q, and 17p in advanced urothelial cancer and lack of relation to chemotherapy response and outcome.
Sengeløv L; Christensen M; von der Maase HD; Horn T; Marcussen N; Kamby C; Orntoft T
Cancer Genet Cytogenet; 2000 Dec; 123(2):109-13. PubMed ID: 11156735
[TBL] [Abstract][Full Text] [Related]
38. [Molecular changes in development and progression of urothelial carcinoma].
Hartmann A
Verh Dtsch Ges Pathol; 2003; 87():172-84. PubMed ID: 16888910
[TBL] [Abstract][Full Text] [Related]
39. Initiation-development modelling of allelic losses on chromosome 9 in multifocal bladder cancer.
Louhelainen J; Wijkström H; Hemminki K
Eur J Cancer; 2000 Jul; 36(11):1441-51. PubMed ID: 10899659
[TBL] [Abstract][Full Text] [Related]
40. Histologic-genetic mapping by allele-specific PCR reveals intraurothelial spread of p53 mutant tumor clones.
Stoehr R; Knuechel R; Boecker J; Blaszyk H; Schmitt R; Filbeck T; Hofstaedter F; Hartmann A
Lab Invest; 2002 Nov; 82(11):1553-61. PubMed ID: 12429815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
